There was no significant difference in disease-free survival probability or overall survival between PALB2 mutation breast carriers and the mutation-negative breast cancer group, as well as to those with the BRCA1/2 mutation group in pairwise comparisons (Supplementary Figures S1 and S2). This evidence concerns the gene BRCA1 and breast carcinoma.